|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
<i>Thioredoxin reductase 1</i> (<i>TXNRD1</i>) is an antioxidant enzyme reportedly overexpressed in hepatocellular carcinoma (HCC); however, the detailed function and mechanisms of TXNRD1 in HCC remain obscure.
|
31384178 |
2019 |
|
Sjogren-Larsson Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Sjogren - Larsson syndrome (SLS) is a rare autosomal recessive disease of the mutation ALDH3A2 that identifies a part of fatty acids for fatty aldehyde dehydrogenase: NAD-oxidoreductase enzyme complex.
|
31697031 |
2019 |
|
Malignant tumor of colon
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Thioredoxin reductase 1 expression in colon cancer: discrepancy between in vitro and in vivo findings.
|
13679440 |
2003 |
|
Colon Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Thioredoxin reductase 1 expression in colon cancer: discrepancy between in vitro and in vivo findings.
|
13679440 |
2003 |
|
Amyotrophic Lateral Sclerosis, Familial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Thioredoxin reductase 1 haplotypes modify familial amyotrophic lateral sclerosis onset.
|
18996185 |
2009 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) is a key regulator in many redox-dependent cellular pathways, and is often overexpressed in cancer.
|
19838062 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) is a key regulator in many redox-dependent cellular pathways, and is often overexpressed in cancer.
|
19838062 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TXNRD1 overexpression rescued tumors from AF-TUSC2-erlotinib induced apoptosis.
|
27845352 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thioredoxin reductase 1 (TXNRD1) which is a selenocysteine-containing protein is overexpressed in many malignancies.
|
28536696 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) is a cancer target and essential selenoprotein that defends the cell against reactive oxygen species and regulates cellular signaling and redox pathways.
|
29117711 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) is a cancer target and essential selenoprotein that defends the cell against reactive oxygen species and regulates cellular signaling and redox pathways.
|
29117711 |
2018 |
|
Respiratory Distress Syndrome, Adult
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thioredoxin reductase-1 (TXNRD1) inhibition effectively activates nuclear factor (erythroid-derived 2)-like 2 (Nrf2) responses and attenuates lung injury in acute respiratory distress syndrome (ARDS) and bronchopulmonary dysplasia (BPD) models.
|
30024305 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) has emerged as a potential target for cancer therapy, because it is overexpressed in several types of cancers and associated with increased tumour growth and poor patient prognosis.
|
30668191 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Thioredoxin reductase 1 (TrxR1) has emerged as a potential target for cancer therapy, because it is overexpressed in several types of cancers and associated with increased tumour growth and poor patient prognosis.
|
30668191 |
2019 |
|
Bronchopulmonary Dysplasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thioredoxin Reductase-1 Inhibition Augments Endogenous Glutathione-Dependent Antioxidant Responses in Experimental Bronchopulmonary Dysplasia.
|
30805084 |
2019 |
|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.
|
31097586 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TrxR1 activity in gastric cells or tumor tissues was determined by the endpoint insulin reduction assay.
|
31113439 |
2019 |
|
trachomatis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Oxidoreductase disulfide bond proteins DsbA and DsbB form an active redox pair in Chlamydia trachomatis, a bacterium with disulfide dependent infection and development.
|
31536549 |
2019 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TR1 gene maps to chromosome 8q23-24.1 and its mRNA is abundantly expressed on primary osteoblasts, osteogenic sarcoma cell lines, and primary fibroblasts.
|
9657524 |
1998 |
|
Mitochondrial Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
A popular mouse model of mitochondrial disease that lacks NADH:ubiquinone oxidoreductase subunit S4 (NDUFS4), a subunit of mitochondrial complex I, phenocopies many traits of the human disease Leigh syndrome, including the development of optic atrophy.
|
31248988 |
2019 |
|
Leigh Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
A popular mouse model of mitochondrial disease that lacks NADH:ubiquinone oxidoreductase subunit S4 (NDUFS4), a subunit of mitochondrial complex I, phenocopies many traits of the human disease Leigh syndrome, including the development of optic atrophy.
|
31248988 |
2019 |
|
Optic Atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
A popular mouse model of mitochondrial disease that lacks NADH:ubiquinone oxidoreductase subunit S4 (NDUFS4), a subunit of mitochondrial complex I, phenocopies many traits of the human disease Leigh syndrome, including the development of optic atrophy.
|
31248988 |
2019 |
|
Bullous pemphigoid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total of four single nucleotide polymorphisms (SNPs) in the mtDNA, namely, m.16263T>C, m.16051A>G, and m.16162A>G in the D-loop region of the mtDNA, and m.11914G>A in the mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 gene (<i>MT-ND4</i>), were found to be significantly associated with BP based on the meta-analysis of our NGS data and the Sanger sequencing data (<i>p</i> = 0.0017, <i>p</i> = 0.0129, <i>p</i> = 0.0076, and <i>p</i> = 0.0132, respectively, Peto's test).
|
31824475 |
2019 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abbreviations: 3-MA: 3-methyladenine; AR7: 7-chloro-3-(4-methylphenyl)-2H-1,4-benzoxazine; CMA: chaperone-mediated autophagy; CQ: chloroquine; CSF: cerebrospinal fluid; DDM: n-dodecyl β-D-maltoside; DIV: days in vitro; ELISA: enzyme-linked immunosorbent assay; FACS: fluorescence-activated cell sorting; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GWAS: genome-wide association studies; HSPA8/HSC70: heat shock protein 8; KFERQ: CMA recognition pentapeptide; KI: knockin; LAMP1: lysosomal-associated membrane protein 1; LAMP2A: lysosomal-associated membrane protein 2A; LDH: lactate dehydrogenase; LRRK2: leucine-rich repeat kinase 2; MEF: mouse embryonic fibroblast; NDUFS4: NADH:ubiquinone oxidoreductase core subunit S4; NE: novel epitope; PD: Parkinson disease; RARA/RARα: retinoic acid receptor, alpha; SNCA: synuclein, alpha; TUBB3/TUJ1: tubulin, beta 3 class III; WT: wild-type.
|
30983487 |
2020 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Aberrant overexpression of endoplasmic reticulum (ER)-resident oxidoreductase protein disulfide isomerase (PDI) plays an important role in cancer progression.
|
31149044 |
2019 |